Update on Pretomanid,in Combination with
Bedaquiline and Linezolid (the BPaLRegimen) in
Drug-Resistant TB

Results from the ZeNix trial showed that the BPaL combination of drugs remains effective against highly drug resistant tuberculosis (TB) with reduced dosage or duration of the Linezolid part of the regimen.  The study tested a version of BPaL with a lower dose and shorter duration of Linezolid, to determine whether the efficacy of BPaL can be maintained while reducing toxicity.  ZeNix enrolled patients with XDR-TB at study sites in Africa and Eastern Europe.The ZeNix trial is funded and sponsored by the TB Alliance (TBA) and led by the MRC Clinical Trials Unit (CTU) at University College London (UCL).

Details can be found in the following presentation from TBA.